Article
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Nature communications - 28 Feb 2024
Fonseca Nicolette M, Maurice-Dror Corinne, Herberts Cameron, Tu Wilson, Fan William, Murtha Andrew J, Kollmannsberger Catarina, Kwan Edmond M, Parekh Karan, Schönlau Elena, Bernales Cecily Q, Donnellan Gráinne, Ng Sarah W S, Sumiyoshi Takayuki, Vergidis Joanna, Noonan Krista, Finch Daygen L, Zulfiqar Muhammad, Miller Stacy, Parimi Sunil, Lavoie Jean-Michel, Hardy Edward, Soleimani Maryam, Nappi Lucia, Eigl Bernhard J, Kollmannsberger Christian, Taavitsainen Sinja, Nykter Matti, Tolmeijer Sofie H, Boerrigter Emmy, Mehra Niven, van Erp Nielka P, De Laere Bram, Lindberg Johan, Grönberg Henrik, Khalaf Daniel J, Annala Matti, Chi Kim N, Wyatt Alexander W
Abstract excerpt
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is unclear. Here, we intersect ctDNA%, treatment outcomes, and clinical characteristics across 738 plasma samples from 491 male mCRPC patients from two randomized...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.